MPD-75
MPD-75, also known as 1-methyl-N-pyrrolidyllysergamide or as 1-methyllysergic acid pyrrolidide, is a psychedelic drug of the lysergamide family related to lysergic acid diethylamide. It is the 1-methyl derivative of lysergic acid pyrrolidide and the N-pyrrolidide analogue of 1-methyl-LSD. Extensive metabolism of other 1-methylated lysergamides to their secondary amine derivatives, for instance methysergide conversion into methylergometrine, has been observed.
MPD-75 was evaluated in humans and was found to produce partial LSD-like effects. It was reported to have had a faster onset and shorter duration compared to LSD. MPD-75 showed less than 5% of the potency of LSD in producing LSD-like effects, with a required dose of >20μg/kg or >1.6mg orally. According to another source however, MPD-75 had 7% of the potency of LSD in humans. For comparison, LA-Pyr had approximately 10% of the potency of LSD and had more full LSD-like effects, while 1-methyl-LSD had 33% of the potency of LSD and likewise produced full LSD-like effects.
Pharmacology
Pharmacodynamics
In animal studies, MPD-75 had 4% of the toxicity of LSD in rabbits, 0% of its pyretogenic activity in rabbits, and 130% of its antiserotonergic activity in the isolated rat uterus.
History
MPD-75 was first described in the scientific literature by Albert Hofmann and colleagues by 1957. It has not been encountered as a designer drug as of 2020.